{
    "ticker": "HLVX",
    "name": "HilleVax, Inc.",
    "description": "HilleVax, Inc. is a biotechnology company focused on developing innovative vaccines to address significant unmet medical needs. Founded in 2021, HilleVax is dedicated to creating solutions for infectious diseases, particularly targeting viral infections that pose substantial public health challenges. The company's lead product candidate is a vaccine designed to protect against norovirus, a highly contagious virus that causes gastrointestinal illness and is a leading cause of foodborne outbreaks worldwide. HilleVax's proprietary technology platform leverages advanced vaccine design and development methodologies, aiming to produce effective and safe vaccines that can be rapidly deployed in response to outbreaks. The company's mission is to improve health outcomes globally by providing preventative solutions that can reduce the burden of infectious diseases. HilleVax is committed to scientific excellence and collaboration with leading research institutions and public health organizations to advance its vaccine candidates through clinical development. With a strong leadership team comprising seasoned professionals with extensive experience in vaccine development and commercialization, HilleVax is poised to make significant contributions to public health.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Boston, Massachusetts, USA",
    "founded": "2021",
    "website": "https://www.hillevax.com",
    "ceo": "Thomas K. G. Hilleman",
    "social_media": {
        "twitter": "https://twitter.com/HilleVax",
        "linkedin": "https://www.linkedin.com/company/hillevax/"
    },
    "investor_relations": "https://www.hillevax.com/investor-relations",
    "key_executives": [
        {
            "name": "Thomas K. G. Hilleman",
            "position": "CEO"
        },
        {
            "name": "Jennifer C. Smith",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Vaccines",
            "products": [
                "Norovirus Vaccine"
            ]
        }
    ],
    "seo": {
        "meta_title": "HilleVax, Inc. | Innovative Vaccines for Infectious Diseases",
        "meta_description": "Explore HilleVax, Inc., a biotechnology firm developing advanced vaccines to combat viral infections. Learn about our mission and innovative vaccine candidates.",
        "keywords": [
            "HilleVax",
            "Vaccines",
            "Norovirus",
            "Infectious Diseases",
            "Biotechnology"
        ]
    },
    "faq": [
        {
            "question": "What is HilleVax known for?",
            "answer": "HilleVax is known for developing innovative vaccines, particularly targeting norovirus."
        },
        {
            "question": "Who is the CEO of HilleVax?",
            "answer": "Thomas K. G. Hilleman is the CEO of HilleVax, Inc."
        },
        {
            "question": "Where is HilleVax headquartered?",
            "answer": "HilleVax is headquartered in Boston, Massachusetts, USA."
        },
        {
            "question": "What are HilleVax's main products?",
            "answer": "HilleVax's main product candidate is a vaccine for norovirus."
        },
        {
            "question": "When was HilleVax founded?",
            "answer": "HilleVax was founded in 2021."
        }
    ],
    "competitors": [
        "NVAX",
        "VZIO",
        "MRNA"
    ],
    "related_stocks": [
        "PFE",
        "JNJ",
        "BMY",
        "GILD"
    ]
}